FGF9 from cancer-associated fibroblasts is a possible mediator of invasion and anti-apoptosis of gastric cancer cells

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Sun, Chao ^a,b   Fukui, Hirokazu ^a   Hara, Ken ^a   Zhang, Xinxing ^a,c   Kitayama, Yoshitaka ^a   Eda, Hirotsugu ^a   Tomita, Toshihiko ^a   Oshima, Tadayuki ^a   Kikuchi, Shojiro ^a   Watari, Jiro ^a   Sasako, Mitsuru ^a   Miwa, Hiroto ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Akt; Anti apoptosis; Cancer associated fibroblast; ERK; FGF; Gastric cancer; Invasion

Indexed keywords

FIBROBLAST GROWTH FACTOR 9; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; FGF9 PROTEIN, HUMAN; MATRILYSIN; MMP7 PROTEIN, HUMAN; NEUTRALIZING ANTIBODY; TUMOR MARKER;

ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; FGF9 GENE; FIBROBLAST; GASTRIC CANCER CELL LINE; GENE FUNCTION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR INVASION; WESTERN BLOTTING; APOPTOSIS; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANTIBODIES, NEUTRALIZING; APOPTOSIS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL PROLIFERATION; FIBROBLAST GROWTH FACTOR 9; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 7; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84928880350     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1353-3     Document Type: Article

References (32)

1. Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci. 2010;15:166-79.
2. Silzle T, Randolph GJ, Kreutz M, Kunz-Schughart LA. The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer. 2004;108:173-80.
3. Mishra P, Banerjee D, Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol. 2011;89:31-9.
4. Marsh T, Pietras K, McAllister SS. Fibroblasts as architects of cancer pathogenesis. Biochim Biophys Acta. 1832;2013:1070-8.
5. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332-7.
6. Giri D, Ropiquet F, Ittmann M. FGF9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells. J Cell Physiol. 1999;180:53-60.
7. Coffey E, Newman DR, Sannes PL. Expression of fibroblast growth factor 9 in normal human lung and idiopathic pulmonary fibrosis. J Histochem Cytochem. 2013;61:671-9.
8. Tsai SJ, Wu MH, Chen HM, Chuang PC, Wing LY. Fibroblast growth factor-9 is an endometrial stromal growth factor. Endocrinology. 2002;143:2715-21.
9. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116-29.
10. Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 2001;61:3541-3.
11. Fukui H, Fujii S, Takeda J, Kayahara T, Sekikawa A, Nanakin A, et al. Expression of Reg Iα protein in human gastric cancers. Digestion. 2004;69:177-84.
12. Wang CK, Chang H, Chen PH, Chang JT, Kuo YC, Ko JL, et al. Aryl hydrocarbon receptor activation and overexpression upregulated fibroblast growth factor-9 in human lung adenocarcinomas. Int J Cancer. 2009;125:807-15.
13. Fukui H, Sekikawa A, Tanaka H, Fujimori Y, Katake Y, Fujii S, et al. DMBT1 is a novel gene induced by IL-22 in ulcerative colitis. Inflamm Bowels Dis. 2011;17:1177-88.
14. Sekikawa A, Fukui H, Fujii S, Ichikawa K, Tomita S, Imura J, et al. REG Iα protein mediates an anti-apoptotic effect of STAT3 signaling in gastric cancer cells. Carcinogenesis. 2008;29:76-83.
15. Fukui H, Zhang X, Sun C, Hara K, Kikuchi S, Yamasaki T, et al. IL-22 produced by cancer-associated fibroblasts promotes gastric cancer cell invasion via STAT3 and ERK signaling. Br J Cancer. 2014;111:763-71.
16. Lai MS, Cheng YS, Chen PR, Tsai SJ, Huang BM. Fibroblast growth factor 9 activates akt and MAPK pathways to stimulate steroidogenesis in mouse leydig cells. PLoS One. 2014;9:e90243.
17. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res. 2006;66:1354-62.
18. Chen SF, Nieh S, Jao SW, Wu MZ, Liu CL, Chang YC, et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol. 2013;231:180-9.
19. Peng Q, Zhao L, Hou Y, Sun Y, Wang L, Luo H, et al. Biological characteristics and genetic heterogeneity between carcinoma-associated fibroblasts and their paired normal fibroblasts in human breast cancer. PLoS One. 2013;8:e60321.
20. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res. 2011;1:482-97.
21. Petersen OW, Nielsen HL, Gudjonsson T, Villadsen R, Rank F, Niebuhr E, et al. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol. 2003;162:391-402.
22. Rasanen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res. 2010;316:2713-22.
23. Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation. 2007;75:831-42.
24. Teishima J, Shoji K, Hayashi T, Miyamoto K, Ohara S, Matsubara A. Relationship between the localization of fibroblast growth factor 9 in prostate cancer cells and postoperative recurrence. Prostate Cancer Prostatic Dis. 2012;15:8-14.
25. Matsumoto-Yoshitomi S, Habashita J, Nomura C, Kuroshima K, Kurokawa T. Autocrine transformation by fibroblast growth factor 9 (FGF-9) and its possible participation in human oncogenesis. Int J Cancer. 1997;71:442-50.
26. Deng M, Tang HL, Lu XH, Liu MY, Lu XM, Gu YX, et al. miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer. PLoS One. 2013;8:e72662.
27. Lum M, Turbic A, Mitrovic B, Turnley AM. Fibroblast growth factor-9 inhibits astrocyte differentiation of adult mouse neural progenitor cells. J Neurosci Res. 2009;87:2201-10.
28. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 2010, 141: 52-67.
29. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993;4:197-250.
30. Sakamoto N, Naito Y, Oue N, Sentani K, Uraoka N, Zarni Oo H, et al. MicroRNA-148a is downregulated in gastric cancer, targets MMP7, and indicates tumor invasiveness and poor prognosis. Cancer Sci. 2014;105:236-43.
31. Koskensalo S, Mrena J, Wiksten JP, Nordling S, Kokkola A, Hagstrōm J, et al. MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol. 2010;31:149-55.
32. Wang WS, Chen PM, Wang HS, Liang WY, Su Y. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis. 2006;27:1113-20.